25 results on '"Fishman, Marc L."'
Search Results
2. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act
3. Effective complementary ASCO policy and day to day decision support strategies optimize anti-emetic choices.
4. Community platinum use in neoadjuvant or adjuvant HER2- breast cancer.
5. Quality and value-focused albumin-bound paclitaxel decision support for pancreatic, lung, and breast cancer in southeastern United States.
6. Quality and value implications of NCCN-compliant use of maintenance rituximab for patients with low-grade NHL.
7. Adjuvant chemotherapy selection for stage I NSCLC 2011 through 2014 in the southeastern United States.
8. Adjuvant colon cancer care quality, risk, value, and level one data and guideline compliance among the elderly privately insured in southeastern USA.
9. Overuse of five expensive oncology pharmaceuticals in the southeastern United States: A physician-level analysis.
10. Effect of Oncology Analytics (OA) cancer care quality initiative on inappropriate use of erythropoiesis stimulating agents (ESA) among cancer patients receiving chemotherapy with curative intent.
11. Use, misuse, and overuse of white cell growth factors (GF) in community oncology practices in southeastern United States.
12. Adjuvant colon cancer care compliance with level I data and NCCN guidelines in the elderly population.
13. Evidence-based adjuvant chemotherapy for NSCLC in southeastern United States.
14. Ensuring evidence-based cancer medicine by influencing prescribing behavior.
15. Trends in the use of bone agents in metastatic cancer.
16. Effect of pretreatment clinical consultation on oncologist prescribing behavior in the initial treatment of NSCLC.
17. Improving QOL and safety while reducing costs: Evidence-based adjuvant chemotherapy of colorectal cancer (CRC).
18. Community use of anthracyclines in metastatic breast cancer (MBC).
19. Off-label capecitabine, eribulin, or ixabepilone use in metastatic breast cancer (MBC).
20. Community use of anthracyclines for adjuvant HER2-positive breast cancer (BC).
21. Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences
22. Interpretation of surrogate endpoints in clinical trials.
23. Mallory-Weiss tear. A complication of cancer chemotherapy
24. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act
25. Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.